Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Nature Communications|February 5, 2026
A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responsesAbigail E Powell, Hannah Caruso, Soyoon Park, et al.
Med (New York, N.Y.)|July 23, 2022
Acute HIV-1 infection viremia associate with rebound upon treatment interruptionThembi Mdluli, Yifan Li, Suteeraporn Pinyakorn, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Nature Communications|October 8, 2021
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaquesRamon Roozendaal, Laura Solforosi, Daniel J Stieh, et al.
Cell Reports|June 8, 2024
Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruptionThembi Mdluli, Bonnie M Slike, Daniel J Curtis, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Pageof 4